1-(4-methylpiperazin-1-yl)-3-(5-nitrofuran-2-yl)prop-2-en-1-one, also known as **nitrofurazone**, is an **antibacterial agent** with a long history of use in human and veterinary medicine.
Here's a breakdown of its structure and importance:
**Structure:**
* **Nitrofuran moiety:** The 5-nitrofuran-2-yl group is the core structural feature responsible for nitrofurazone's antimicrobial activity. It acts as an electron acceptor, interfering with bacterial metabolism.
* **Piperazine ring:** The 4-methylpiperazin-1-yl group contributes to the molecule's overall shape and solubility, influencing its absorption and distribution in the body.
* **Enone system:** The prop-2-en-1-one moiety, also known as an enone, is a conjugated double bond system, which contributes to the molecule's stability and potential interactions with biological targets.
**Importance in Research:**
* **Broad-spectrum activity:** Nitrofurazone exhibits broad-spectrum antibacterial activity, effective against a wide range of Gram-positive and Gram-negative bacteria.
* **Topical applications:** Primarily used topically for wound and burn infections, nitrofurazone has been particularly effective in treating superficial skin infections.
* **Mechanism of action:** Research into the precise mechanism of action of nitrofurazone is ongoing, but it is believed to interfere with bacterial DNA synthesis and other essential metabolic processes.
* **Antibacterial resistance:** Although nitrofurazone has shown effectiveness against many bacteria, resistance can develop. Researchers continue to explore its potential uses and investigate new derivatives that might overcome resistance issues.
* **New formulations:** Researchers are exploring new formulations of nitrofurazone to improve its delivery, efficacy, and safety.
**Research Focus:**
Current research focuses on:
* **Developing new derivatives:** Scientists are synthesizing and studying new derivatives of nitrofurazone to enhance its antimicrobial properties, increase its stability, and overcome resistance issues.
* **Investigating mechanisms of action:** Further understanding of the mechanisms of action of nitrofurazone will enable the development of new and more effective antibacterial agents.
* **Exploring alternative applications:** Researchers are investigating the potential of nitrofurazone in other areas, such as antifungal or antiviral applications.
**Overall, nitrofurazone remains a valuable tool for research into antibacterial drug development and treatment strategies.** Its unique structure and broad-spectrum activity continue to inspire the exploration of new and improved antimicrobial therapies.
1-(4-methylpiperazin-1-yl)-3-(5-nitrofuran-2-yl)prop-2-en-1-one: a p73 protein-stimulating compound that restores p53 signaling; structure in first source
ID Source | ID |
---|---|
PubMed CID | 5356520 |
CHEMBL ID | 1979662 |
SCHEMBL ID | 17071991 |
SCHEMBL ID | 17654893 |
MeSH ID | M000612902 |
Synonym |
---|
nsc59984 |
mls000737358 , |
nsc-59984 |
smr000528276 |
(e)-1-(4-methylpiperazin-1-yl)-3-(5-nitrofuran-2-yl)prop-2-en-1-one |
1-(4-methylpiperazin-1-yl)-3-(5-nitrofuran-2-yl)prop-2-en-1-one |
HMS2885J20 |
(e)-1-(4-methyl-1-piperazinyl)-3-(5-nitro-2-furanyl)-2-propen-1-one |
cid_5356520 |
bdbm96260 |
(e)-1-(4-methylpiperazino)-3-(5-nitro-2-furyl)prop-2-en-1-one |
S8106 |
CS-5382 |
HY-19726 |
CHEMBL1979662 |
AC-32965 |
803647-40-7 |
nsc 59984 |
SCHEMBL17071991 |
J-690353 |
n-[1,3-dimethyl-2-oxo-6-(1-pyrrolidinyl)-2,3-dihydro-1h-benzimidazol-5-yl]-2-methoxybenzamide |
SCHEMBL17654893 |
EX-A776 |
AKOS030525998 |
nsc59984, >=98% (hplc) |
mfcd29905462 |
BCP16647 |
BS-18159 |
A13413 |
EN300-21685041 |
(2e)-1-(4-methylpiperazin-1-yl)-3-(5-nitrofuran-2-yl)prop-2-en-1-one |
CCG-267098 |
nsc59984,nci59984 |
(2e)-1-(4-methyl-1-piperazinyl)-3-(5-nitro-2-furyl)-2-propen-1-one |
EN300-245475 |
2643927-71-1 |
Z116302242 |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 25.1189 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
Nrf2 | Homo sapiens (human) | Potency | 5.6809 | 0.0920 | 8.2222 | 23.1093 | AID624171; AID651593 |
glp-1 receptor, partial | Homo sapiens (human) | Potency | 3.9811 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 10.0000 | 0.1000 | 20.8793 | 79.4328 | AID588453 |
ATAD5 protein, partial | Homo sapiens (human) | Potency | 12.9900 | 0.0041 | 10.8903 | 31.5287 | AID504466 |
TDP1 protein | Homo sapiens (human) | Potency | 11.8905 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
Microtubule-associated protein tau | Homo sapiens (human) | Potency | 19.9526 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 17.7828 | 0.1000 | 22.9075 | 100.0000 | AID485364 |
Smad3 | Homo sapiens (human) | Potency | 11.2202 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
67.9K protein | Vaccinia virus | Potency | 11.2202 | 0.0001 | 8.4406 | 100.0000 | AID720580 |
P53 | Homo sapiens (human) | Potency | 22.3872 | 0.0731 | 9.6858 | 31.6228 | AID504706 |
IDH1 | Homo sapiens (human) | Potency | 29.0929 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 18.3564 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 25.1189 | 0.4256 | 12.0591 | 28.1838 | AID504891 |
urokinase-type plasminogen activator precursor | Mus musculus (house mouse) | Potency | 2.8184 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
plasminogen precursor | Mus musculus (house mouse) | Potency | 2.8184 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
urokinase plasminogen activator surface receptor precursor | Mus musculus (house mouse) | Potency | 2.8184 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 23.3507 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
geminin | Homo sapiens (human) | Potency | 20.5962 | 0.0046 | 11.3741 | 33.4983 | AID624296 |
muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 12.5893 | 0.0041 | 9.9625 | 28.1838 | AID2675 |
DNA dC->dU-editing enzyme APOBEC-3F isoform a | Homo sapiens (human) | Potency | 6.3096 | 0.0259 | 11.2398 | 31.6228 | AID602313 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
exodeoxyribonuclease V subunit RecB | Escherichia coli str. K-12 substr. MG1655 | IC50 (µMol) | 39.4930 | 0.1000 | 0.1000 | 0.1000 | AID652151 |
exodeoxyribonuclease V subunit RecC | Escherichia coli str. K-12 substr. MG1655 | IC50 (µMol) | 39.4930 | 0.1000 | 0.1000 | 0.1000 | AID652151 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (11.11) | 29.6817 |
2010's | 6 (66.67) | 24.3611 |
2020's | 2 (22.22) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.25) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (11.11%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 8 (88.89%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |